{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-001688","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2021-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.190699+00:00","generated_at":"2026-06-29T05:29:18.846842+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcadia Biosciences launches CEO search; Matt Plavan to step down when successor named","bullets":["National CEO search underway as Arcadia expands CPG portfolio; successor expected by year-end 2021.","CEO Matt Plavan will step down once successor is named; he has led since 2019, transitioning Arcadia from ag-biotech to CPG.","Transition Agreement: if terminated without cause before Dec 1 2021, Plavan receives $30,833/month consulting through Nov 30 2021.","Severance: $61,666 on Jan 1 2022, $61,666 on Feb 1 2022, $143,278 on Mar 1 2022; full option vesting conditioned on release.","Chairman Kevin Comcowich thanked Plavan for leading through a critical transformation and pandemic."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-001688","json":"https://secwatch.observer/filing/0000950170-21-001688.json","markdown":"https://secwatch.observer/filing/0000950170-21-001688.md","text":"https://secwatch.observer/filing/0000950170-21-001688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000095017021001688/0000950170-21-001688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000095017021001688/rkda-20210903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T05:29:18.846842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da61e3e124","claim":"Matthew Plavan departed as Chief Executive Officer at Arcadia Biosciences, Inc..","evidence_excerpt":"the Company and Matthew Plavan, the Company’s current Chief Executive Officer, entered into a Transition Agreement on September 3, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017021001688/0000950170-21-001688-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}